Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Australian TGA Approves EndoBarrier Gastrointestinal Liner

Australian Therapeutic Goods Administration (TGA) has approved 12 months of treatment for its EndoBarrier Gastrointestinal Liner (the EndoBarrier) to treat patients with Type 2 diabetes and obesity.

Following this approval, EndoBarrier can be commercially launched in Australia.

The EndoBarrier is implanted non-surgically through mouth without cutting any tissue to create a barrier between wall of the intestine and food.

The TGA approval is based on the 500-patient clinical study that demonstrated EndoBarrier improves glycemic control and weight loss over the treatment period.

According to the Australian Diabetes Council (ADC), over 3 million Australian adults above the age of 25 have either diabetes or pre-diabetes.

The EndoBarrier is approved and commercially available in Chile, Europe, Germany, Netherlands and the United Kingdom.